Wave Life Sciences Second Quarter 2026 Financial Results Scheduled for July 30, 2026
Rhea-AI Summary
Wave Life Sciences (Nasdaq: WVE) will host a live webcast and conference call at 8:30 a.m. ET on Thursday, July 30, 2026, to review its second quarter 2026 financial results and provide business updates.
Investors can access the event via the “Investor Events” section of the company’s website, and an archived webcast will be available there following the live event.
Positive
- None.
Negative
- None.
News Market Reaction – WVE
In the Jul 23 session, WVE gained 0.70%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 28 | First-quarter results | Positive | +8.4% | Reported first-quarter results with cash runway extending into third quarter 2028. |
| Apr 22 | Earnings scheduling | Neutral | -0.5% | Scheduled the first-quarter results webcast and business update for April 28. |
| Feb 26 | Full-year results | Positive | +5.6% | Reported full-year results, cash resources and progress across multiple clinical programs. |
| Feb 19 | Earnings scheduling | Neutral | +0.5% | Scheduled fourth-quarter and full-year results and the accompanying business update. |
| Nov 10 | Third-quarter results | Positive | -10.3% | Reported positive clinical data and cash runway extending into second quarter 2027. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Tag-specific earnings history showed positive reactions to two results releases, divergence on one results release, and non-neutral moves on both scheduling notices.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, July 30, 2026, to review the company’s second quarter 2026 financial results and provide business updates.
The webcast and conference call may be accessed by visiting “Investor Events” on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events.
Analysts planning to participate during the Q&A portion of the live call can join the conference call at the audio-conferencing link here.
Following the live event, an archived version of the webcast will be available on the Wave Life Sciences website.
About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s PRISM® platform combines multiple modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.
Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827
Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com
Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com
